An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vifor Pharma appoints two new members to the Executive Committee
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Vifor Pharma Group has appointed Alexandros Sigalas as acting Chief Financial Officer and Dr. Oliver P. Kronenberg as Group General Counsel, effective February 1, 2022. Sigalas, a 13-year veteran at Vifor, succeeds Colin Bond, who retired at the end of 2021. Dr. Kronenberg, with extensive experience since joining Vifor in 2008, returns to his role after heading legal at Galenica Group. These strategic appointments aim to enhance financial and legal leadership during the company’s transformational phase.
Positive
New appointments are expected to strengthen financial and legal leadership during Vifor Pharma's transformation.
Alexandros Sigalas has a long tenure at Vifor and proven expertise as Global Head of Finance.
Negative
Colin Bond's retirement could signal continuity challenges during the transition period.
Potential experience gaps may arise with recent leadership changes.
Executive appointments to strengthen financial and legal leadership during the transformation of the company
ST. GALLEN, Switzerland--(BUSINESS WIRE)--
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr. Oliver P. Kronenberg as members of the Vifor Pharma Executive Committee, effective 1 February 2022.
Alexandros Sigalas, a 13-year Executive at Vifor Pharma and currently Global Head of Finance, will become acting Chief Financial Officer and succeeds Colin Bond who retired from the company at the end of 2021 at his own request. The Swiss citizen holds a Licentiate Degree (M.Sc.) in Accounting and Business Management from University of St. Gallen and is a Certified Public Accountant in Switzerland.
Dr. Oliver P. Kronenberg, a Swiss citizen, joined Vifor Pharma in 2008. Following his tenure as Group General Counsel of Galenica Group from 2013 until the successful IPO of Galenica Santé in 2017, he resumed his previous role as Group General Counsel of Vifor Pharma. He holds a PhD in law from University of Basel, an LL.M. degree from the College of Europe in Bruges, Belgium, and has completed the Finance for Executives program at INSEAD.
Abbas Hussain, Chief Executive Officer of Vifor Pharma Group, commented: “I am pleased to welcome Alex and Oliver to the Executive Committee. Both are experienced and highly valued leaders of our organization who have a proven track record in their areas of expertise and are dedicated to our mission."
About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
